Active Ingredient History

  • Now
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.   NCATS

  • SMILES: C[C@@H]1CCN(CCN1C(=O)C2=CC(C)=CC=C2N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5
  • Mol. Mass: 450.921
  • ALogP: 4.11
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$8.4650 - $12.2906
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone | [(7r)-4-(5-chlor-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanon | [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone | [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-méthyl-1,4-diazépan-1-yl][5-méthyl-2-(2h-1,2,3-triazol-2-yl)phényl]méthanone | [(7r)-4-(5-chlorobenzoxazol-2-yl)-7-methylhexahydro-1h-1,4-diazepin-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone | belsomra | methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)- | mk4305 | mk 4305 | mk-4305 | suvorexant


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue